Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it ...

Wearable accelerometer-based real-life walking speed monitoring can track disability progression earlier and more often than ...

Kesimpta and Ocrevus show similarly strong disease control of relapsing MS, with small differences in relapse and disability ...

Researchers have traced a previously observed link between microscopic organisms in the digestive tract—collectively known as the gut microbiome—and multiple sclerosis. Their study in genetically ...

Most people with multiple sclerosis (MS) are diagnosed between age 20 and 50, though it can occur in children as well as in older adults, according to the National Multiple Sclerosis Society (NMSS).

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients who registered more persistent paramagnetic rim ...

In people with primary progressive multiple sclerosis (PPMS), depressive symptoms measured using the Hospital Anxiety and Depression Scale (HADS) predicted subsequent neurologic disability progression ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.